Baxter International Inc. (NYSE:BAX), a global leader in injectables, anesthesia and drug compounding, today announced five ...

SAN DIEGO -- A fixed-duration oral combination significantly reduced the risk of disease progression or death compared with ...

-Company expects to provide a broader update across oncology and autoimmune indications in mid-2025- ...

Patients treated with Polivy in combination with R-CHP required fewer subsequent treatments, potentially reducing burdens on patients and healthcare systems1 These encouraging five-year results ...

Studies include the Phase III SUNMO trial evaluating the efficacy and safety of subcutaneously administered Lunsumio ® (mosunetuzumab-axgb) in combination with intravenous (IV) Polivy versus IV ...

DelveInsight's 'Lupus Nephritis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline lupus ...

A 13-year-old male patient presented with a primary complaint of reduced vision in both eyes for the past 15 days at LV ...

Washington: During ACR Convergence 2024, the American College of Rheumatology (ACR) unveiled a summary of the 2024 Guideline ...

‘Poly-refractory’ disease affects 2.7% of patients with rheumatoid arthritis (RA) who have failed different groups of biologic disease-modifying antirheumatic drugs (b-DMARDS) and targeted synthetic ...

In tests on patients with breast cancer who were being given chemotherapy drugs doxorubicin (an injection) and cyclophosphamide (a tablet), more hairs grew in areas treated with the gel. The hair was ...

a boxed warning was removed from treatment with the Sandoz injection and is now instead incorporated into the Warnings and Precautions section of the label. The new and revised label indications also ...

Nov 19 (Reuters) - Merck (MRK.N), opens new tab said on Tuesday a study showed its injectable version of cancer drug Keytruda was not inferior to the currently approved intravenous formulation of ...